Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.135
+0.065 (6.07%)
Sep 2, 2026, 3:05 PM EDT - Market open
Immuron Revenue
In the fiscal year ending June 30, 2026, Immuron had annual revenue of 7.71M AUD with 5.85% growth. Immuron had revenue of 3.53M in the half year ending June 30, 2026, with 38.55% growth.
Revenue (ttm)
7.71M AUD
Revenue Growth
+5.85%
P/S Ratio
1.60
Revenue / Employee
1,101,943 AUD
Employees
7
Market Cap
8.55M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 7.71M | 426.60K | 5.85% |
| Jun 30, 2025 | 7.29M | 2.38M | 48.63% |
| Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
| Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
| Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
| Jun 30, 2021 | 145.78K | -2.85M | -95.13% |
| Jun 30, 2020 | 2.99M | 604.81K | 25.33% |
| Jun 30, 2019 | 2.39M | 544.52K | 29.55% |
| Jun 30, 2018 | 1.84M | 446.71K | 31.99% |
| Jun 30, 2017 | 1.40M | 395.12K | 39.47% |
| Jun 30, 2016 | 1.00M | -1.30K | -0.13% |
| Jun 30, 2015 | 1.00M | 21.33K | 2.17% |
| Jun 30, 2014 | 981.05K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 4.70M |
| Ensysce Biosciences | 4.50M |
| Traws Pharma | 2.73M |
| Exicure | 500.00K |
| Creative Medical Technology Holdings | 3.00K |
| Soligenix | 2.34K |
IMRN News
- 6 weeks ago - Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year - GlobeNewsWire
- 1 month ago - Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - GlobeNewsWire
- 4 months ago - Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 - Accesswire
- 4 months ago - Immuron Double Digit 3Q Sales Growth - GlobeNewsWire
- 6 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Accesswire
- 6 months ago - Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Benzinga
- 7 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Accesswire
- 7 months ago - Immuron Reports Continued Sales Growth - GlobeNewsWire